"Challenging market" shrinks BioHeart IPO size
This article was originally published in Clinica
Executive Summary
Just over a year after filing for an IPO, cardiovascular cell-based therapy specialist BioHeart has ended a drawn out gestation period by listing on the Nasdaq Stock Exchange. However, the company cut the number of shares it had intended to float and saw a 65% mark-down on its opening share price when it debuted on February 19.